Literature DB >> 7007083

Dopamine receptors: subtypes, localization and regulation.

I Creese, D R Sibley, S Leff, M Hamblin.   

Abstract

Receptor binding studies with a variety of dopaminergic ligands have confirmed behavioral and biochemical findings that the central nervous system and peripheral nervous system contain several dopamine receptor subtypes. These subtypes can be discriminated on the basis of their agonist-antagonist pharmacological specificities, linkage to adenylate cyclase, cellular location, regulation by guanine neucleotides and ions, and involvement in several human diseases. Although questions remain unanswered, progress is rapidly being made in equating the subgroupings arrived at by these different experimental approaches. Dopamine receptors are regulated by a number of factors. Acutely, guanine nucleotides and some ions regulate agonist but not antagonist binding and are essential for receptor coupling with adenylate cyclase. Chronically, changes in the level of dopaminergic stimulation modulate the number of at least some receptor subtypes, resulting in "up or down regulation." An increase in receptor number appears central to the pathology of Parkinson's disease, tardive dyskinesia, and perhaps schizophrenia. Animal models indicate that it may be possible to exploit inherent capabilities for receptor modulation in clinical therapy. The therapeutic precedents set by the indentification of distinct subtypes of adrenoreceptors. histamine, and cholinergic receptors portends and exciting future for dopamine receptor research.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7007083

Source DB:  PubMed          Journal:  Fed Proc        ISSN: 0014-9446


  10 in total

1.  Vasoactive agents and production of thrombosis during intravascular coagulation. 3. Comparative effects of catecholamines.

Authors:  J G Latour; C Léger-Gauthier
Journal:  Am J Pathol       Date:  1987-03       Impact factor: 4.307

2.  Prolactin unresponsiveness to repeated sulpiride administration in man: recent findings.

Authors:  G P Bernini; M Gasperi; G Gravina; M S Vivaldi; C Del Corso; R Santoni; M Luisi; F Franchi
Journal:  J Endocrinol Invest       Date:  1987-04       Impact factor: 4.256

3.  Reduction of 3H-spiroperidol binding in rat striatum and frontal cortex by chronic amphetamine: dose response, time course and role of sustained dopamine release.

Authors:  E B Nielsen; M Nielsen; C Braestrup
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

4.  Unresponsiveness of prolactin to repeated injection of sulpiride in man.

Authors:  H Cohen; M Pugeat; J Tourniaire; J Bertrand
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Dopamine receptor sensitivity after chronic dopamine agonists. Striatal 3H-spiroperidol binding in mice after chronic administration of high doses of apomorphine, N-n-propylnorapomorphine and dextroamphetamine.

Authors:  W H Riffee; R E Wilcox; D M Vaughn; R V Smith
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

6.  Sensitization of mice to methylphenidate.

Authors:  L Shuster; J Hudson; M Anton; D Righi
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

7.  Differential effects of chronic treatment with chlorpromazine versus cocaine on behavioral responsiveness to nigral GABA receptor stimulation.

Authors:  S E Bachus; K Gale
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

8.  Guanine nucleotides do not inhibit tritiated dopamine agonist binding to bovine striatal membranes.

Authors:  J A Near; H R Mahler
Journal:  Neurochem Res       Date:  1982-07       Impact factor: 3.996

9.  Characteristics of the electrical response to dopamine in neuroblastoma cells.

Authors:  E Kato; T Narahashi
Journal:  J Physiol       Date:  1982-12       Impact factor: 5.182

10.  Cyclic AMP modulation of ion transport across frog retinal pigment epithelium. Measurements in the short-circuit state.

Authors:  S Miller; D Farber
Journal:  J Gen Physiol       Date:  1984-06       Impact factor: 4.086

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.